Abstract: Described herein is a new method for treating diseases such as no«-alcoholic fatty liver disease and non-alcoholic steatohepatitis with a growth hormone secretagogue alone or in combination with a drug selected from a dipeptidyl peptidase-4 antagonist a glucagon-like peptide receptor agonist, a thrazolidinedione, a sodium glucose transport protein 2 antagonist, and metformin. Compositions relating to the same are also provided.

Abstract: Described herein is a new method for treating diseases such as no«--alcoholic fatty liver disease and non-alcoholic steatohepatius with a growth hormone secretagogue alone or in combination with a drug selected from a dipeptidyl peptidase-4 antagonist a glucagon-like peptide receptor agonist, a thrazolidinedione, a sodium glucose transport protein 2 antagonist, arid metformin. Compositions relating to the same are also provided.

Abstract: The motilin receptor has been isolated and cloned, and nucleic acid sequences are given. Two spice variants have been identified. Also, assays for motilin receptor ligands are given. The identification of the cloned motilin receptor may be used to screen and identify compounds which bind to the receptor for use in a variety of gastric conditions, including gastric motility disorders.

Abstract: A mouse growth hormone secretagogue receptor has been isolated, cloned and sequenced. This receptor is characteristic of the G-protein family of receptors. Mouse growth hormone secretagogue receptors may be used to screen and identify compoumds which bind to the mouse growth hormone secretagogue receptor. Such compounds may be used in the treatment of conditions which occur when there is a shortage of growth hormone, such as observed in growth hormone deficient children, elderly patients with musculoskeletal impairment and those recovering from hip fracture and osteoporosis. Targeted disruption of the mouse GHS-R gene may prove useful in elucidation of the mechanism of action and role of the growth hormone secretagogues in human and animal physiology.

Abstract: A novel canine cDNA sequence that encodes the canine growth hormone secretagogue receptor (GHSR) protein is provided. Also provided is canine GHSR protein encoded by the novel cDNA sequence. Methods of expressing canine GHSR protein in recombinant systems are provided. Also provided are methods for identifying agonists and antagonists of the canine GHSR.

Abstract: Growth is improved by utilizing growth enhancement potential methodology to administer a nucleic acid sequence, such as GHRH or an analog, to a female animal, preferably through a parenteral route of administration. Piglets born from sows injected with DNA encoding GHRH are larger, and effects are demonstrated in subsequent pregnancies without additional administration(s) of the vector.

Abstract: A new galanin receptor, GALR3, is described. Also provided are nucleic acids encoding same and various assays to identify ligands particular to said receptor. Ligands so identified are useful for the treatment of obesity, treatment of pain, and treatment of cognitive disorders.

Abstract: A new galanin receptor, GALR3, is described. Also provided are nucleic acids encoding same and various assays to identify ligands particular to said receptor. Ligands so identified are useful for the treatment of obesity, treatment of pain, and treatment of cognitive disorders.

Abstract: This invention is directed to compounds and ligands that bind to peroxisome proliferator activated receptors (PPAR) &ggr;1 and &ggr;2 and which function as antiproliferative, antiviral and antitumour agents. The invention is also directed to the use of PPAR &ggr;1 and &ggr;2 to identify such compounds and methods of using the compounds for medical uses.

Abstract: There are disclosed compounds of formula (I) and pharmaceutical acceptable salts thereof which are useful as antagonists of GnRH and as such may be useful for the treatment of a variety of sex-hormone related conditions.

Abstract: The combination of a metabolic rate modifying agent (e.g., a .beta..sub.3 adrenergic receptor agonist) and a feeding behavior modifying agent (e.g., a NPY5 antagonist) is useful in the treatment of obesity and diabetes, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients. Methods of treating obesity and diabetes are also described.

Abstract: The present invention is directed to ?.sup.35 S!-N-?1(R)-?(1,2-dihydro-1-methanesulfonylspiro?3H-indole-3,4'-piperidin!- 1'-yl)carbonyl!-2-(phenylmethyloxy)ethyl!-2-amino-2-methylpropanamide, and pharmaceutically acceptable salts thereof. This ?.sup.35 S! radioligand is useful in identifying and characterizing cellular receptors which play a role in the activity of growth hormone secretatogogues. In addition, this ?.sup.35 S! radioligand is useful in assays which test compounds for growth hormone secretagogue activity.

Abstract: There are disclosed compounds of formula (I) ##STR1## and pharmaceutically acceptable salts thereof which are useful as antagonists of GnRH and as such may be useful for the treatment of a variety of sex-hormone related and other conditions in both men and women.

Abstract: A novel single stage culture system for avian embryos is disclosed. Premature eggs consisting of about 32 to about 100 cells are collected shortly after ovulation and prepared for culture. The eggs are incubated in a potassium rich bicarbonate solution and the contents of the eggs are transferred to recipient eggshells. The open end of the eggshell is closed and the embryos are turned and incubated in an oxygen enriched atmosphere for about 3-4 days. For the final incubation period the eggs are incubated in an upright position and rocked hourly.

Abstract: Female prenatal, neonatal and postnatal animals are treated with compositions containing steroid biosynthesis inhibitors or antagonists which prevents the conversion of androgens to estrogens. The compositions are useful for improving growth and feed efficiency.